primaquine [Ligand Id: 9952] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL506 (Kanaprim, Maliride, Neo-quipenyl, NSC-27296, Primachin, Primaquine, SN-13272, WR-2975) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| Chloroquine resistance transporter in Plasmodium falciparum (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795182] [UniProtKB: Q9N623] | ||||||||
| ChEMBL | Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-chloroquine transportation after 1 to 2 hrs | B | 4.17 | pIC50 | 68000 | nM | IC50 | ACS Med Chem Lett (2014) 5: 576-581 [PMID:24900883] |
| CYP1A2/Cytochrome P450 1A2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3356] [GtoPdb: 1319] [UniProtKB: P05177] | ||||||||
| ChEMBL | DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | B | 6.74 | pIC50 | 182.4 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| GroEL/GroES in Escherichia coli (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL4106139] [UniProtKB: Q548M1, Q7BGE6] | ||||||||
| ChEMBL | Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme activity using sodium mesoxalate as substrate after 20 to 40 mins by malachite green dye based spectrometric analysis | B | 4.12 | pIC50 | 75000 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 1106-1112 [PMID:30852084] |
| ChEMBL | Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis | B | 5.21 | pIC50 | 6200 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 1106-1112 [PMID:30852084] |
| HSP60/HSP10 in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL4106131] [UniProtKB: P10809, P61604] | ||||||||
| ChEMBL | Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme activity using sodium mesoxalate as substrate after 40 to 60 mins by malachite green dye based spectrometric analysis | B | 4 | pIC50 | >100000 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 1106-1112 [PMID:30852084] |
| Monoamine oxidase A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1951] [GtoPdb: 2489] [UniProtKB: P21397] | ||||||||
| ChEMBL | Inhibition of human recombinant MAOA assessed as conversion of kynuramine to 4-hydroxyquinoline preincubated for 15 mins by fluorimetric assay | B | 4.12 | pIC50 | 75700 | nM | IC50 | Bioorg Med Chem Lett (2012) 22: 1701-1704 [PMID:22264472] |
| Monoamine oxidase B in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2039] [GtoPdb: 2490] [UniProtKB: P27338] | ||||||||
| ChEMBL | Inhibition of human recombinant MAOB assessed as conversion of kynuramine to 4-hydroxyquinoline preincubated for 15 mins by fluorimetric assay | B | 4.02 | pIC50 | 94500 | nM | IC50 | Bioorg Med Chem Lett (2012) 22: 1701-1704 [PMID:22264472] |
| Plasmodium berghei (target type: ORGANISM) [ChEMBL: CHEMBL612653] | ||||||||
| ChEMBL | Antiplasmodial activity against liver stage chloroquine-susceptible Plasmodium berghei 1052 C11 infected in HepG2 cells after 44 hrs by TopCount microplate luminescence assay | F | 4.76 | pIC50 | 17200 | nM | IC50 | Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120] |
| ChEMBL | Antimalarial activity against luciferase-expressing Plasmodium berghei ANKA 676m1cl1 sporozoites infected in human HepG2A16 cells measured after 45 hrs by luciferase-luciferin based reporter gene assay | F | 4.86 | pIC50 | 13800 | nM | IC50 | J Med Chem (2020) 63: 6179-6202 [PMID:32390431] |
| ChEMBL | Antimalarial activity against liver stages of Plasmodium berghei | F | 4.89 | pIC50 | 13000 | nM | IC50 | J Med Chem (2012) 55: 995-1012 [PMID:22122518] |
| ChEMBL | Antiplasmodial activity against liver stage Plasmodium berghei infected in Huh7 cells assessed as inhibition of parasite infection incubated for 1 hr prior to infection measured at 24 hrs by luciferase reporter gene assay | F | 5.02 | pIC50 | 9500 | nM | IC50 | Bioorg Med Chem (2016) 24: 1786-1792 [PMID:26968650] |
| ChEMBL | Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay | F | 5.07 | pIC50 | 8428 | nM | IC50 | Eur J Med Chem (2015) 101: 266-273 [PMID:26142491] |
| ChEMBL | Antimalarial activity against GFP-fused Plasmodium berghei ANKA liver stage infected in HuH7 cells pretreated for 1 hr followed by parasite infection after 48 hrs by luciferase reporter gene assay | F | 5.07 | pIC50 | 8420 | nM | IC50 | J Med Chem (2017) 60: 1432-1448 [PMID:28094524] |
| ChEMBL | Antiplasmodial activity against liver stage luciferase expressing Plasmodium berghei sporozoites infected in human Huh7 cells preincubated with host cells for 1 hr followed by plasmodium infection by bioluminescence assay | F | 5.08 | pIC50 | 8400 | nM | IC50 | Eur J Med Chem (2020) 187: 111927-111927 [PMID:31812035] |
| ChEMBL | Antimalarial activity against Plasmodium berghei infected in human Huh7 cells after 1 hr by luciferase reporter gene assay | F | 5.08 | pIC50 | 8400 | nM | IC50 | Eur J Med Chem (2019) 182: 111640-111640 [PMID:31472472] |
| ChEMBL | Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP-Luc infected in HuH7 cells incubated at 1 hr prior to infection followed by compound replenisment at 24 hrs post-infection measured after 48 hrs by Alamar blue assay | F | 5.1 | pIC50 | 8000 | nM | IC50 | Bioorg Med Chem Lett (2013) 23: 610-613 [PMID:23290049] |
| ChEMBL | Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells after 48 hrs by luciferase assay | F | 5.12 | pIC50 | 7500 | nM | IC50 | ACS Med Chem Lett (2014) 5: 108-112 [PMID:24900781] |
| ChEMBL | Antiplasmodial activity against Plasmodium berghei liver stage form transfected in human Huh-7 cells assessed as cell viability after 48 hrs by luciferase reporter gene assay | F | 5.12 | pIC50 | 7500 | nM | IC50 | J Med Chem (2013) 56: 556-567 [PMID:23273038] |
| ChEMBL | Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay | F | 5.12 | pIC50 | 7500 | nM | IC50 | J Med Chem (2013) 56: 4811-4815 [PMID:23701465] |
| ChEMBL | Antiplasmodial activity against liver stage of Plasmodium berghei ANKA infected in human HepG2 cells | F | 5.12 | pIC50 | 7500 | nM | IC50 | J Nat Prod (2013) 76: 1064-1070 [PMID:23806111] |
| ChEMBL | Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP infected in human Huh7 cells by luminescence assay | F | 5.12 | pIC50 | 7500 | nM | IC50 | J Nat Prod (2013) 76: 1064-1070 [PMID:23806111] |
| ChEMBL | Antiplasmodial activity against liver stage of Plasmodium berghei infected in human HuH7 cells assessed as parasite growth inhibition incubated for 1 hr prior to parasite infection measured after 48 hrs | F | 5.12 | pIC50 | 7500 | nM | IC50 | J Med Chem (2013) 56: 7679-7690 [PMID:24020770] |
| ChEMBL | Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei expressing luciferase and GFP infected in human HuH7 cells assessed as inhibition of parasite development incubated for 1 hr prior to parasite infection measured after 48 hrs by Alamar blue assay | F | 5.12 | pIC50 | 7500 | nM | IC50 | Eur J Med Chem (2013) 69: 872-880 [PMID:24125849] |
| ChEMBL | Antiplasmodial activity against liver stage of Plasmodium berghei sporozoites expressing firefly luciferase infected in human Huh7 cells assessed as inhibition of parasite development treated 1 hr prior to infection followed by compound replenisment at 24 hrs post-infection measured 48 hrs after infection by bioluminescence analysis | F | 5.12 | pIC50 | 7500 | nM | IC50 | Medchemcomm (2012) 3: 1170-1172 |
| ChEMBL | Antimalarial activity against Plasmodium berghei infected in human HuH7 cells assessed as inhibition of liver cell infection | F | 5.12 | pIC50 | 7500 | nM | IC50 | Bioorg Med Chem (2015) 23: 5098-5119 [PMID:25593097] |
| ChEMBL | Antimalarial activity against liver stage form of luciferase transfected Plasmodium berghei sporozoites infected in human HuH7 cells preincubated with host cells for 1 hr followed by plasmodial infection and measured after 48 hrs by bioluminescence method | F | 5.2 | pIC50 | 6250 | nM | IC50 | J Med Chem (2019) 62: 1022-1035 [PMID:30562027] |
| ChEMBL | Antiplasmodial activity against liver stage Plasmodium berghei ANKA sporozoites expressing GFP infected in HepG2 cells pre-infected with cells for 1 hr prior to compound addition and measured after 48 hrs by flow cytometry analysis | F | 5.22 | pIC50 | 6000 | nM | IC50 | J Med Chem (2022) 65: 16695-16715 [PMID:36507890] |
| ChEMBL | Antiplasmodial activity against GFP-harboring Plasmodium berghei sporozoites infected in human HepG2 cells assessed as reduction in parasite growth treated every 24 hrs by DAPI staining-based fluorescence microscopic analysis | F | 5.44 | pIC50 | 3650 | nM | IC50 | Eur J Med Chem (2018) 158: 68-81 [PMID:30199706] |
| ChEMBL | Antiplasmodial activity against GFP-fused Plasmodium berghei sporozoites infected in human HepG2A16 cells treated simultaneously with infection by fluorescence microscopic analysis | F | 5.44 | pIC50 | 3650 | nM | IC50 | Eur J Med Chem (2018) 152: 489-514 [PMID:29754074] |
| ChEMBL | Antiplasmodial activity against luciferase expressing Plasmodium berghei sporozoites infected in human HuH7 cells assessed as reduction in parasite load incubated prior to parasite infection and measured after 48 hrs by bioluminescence assay | F | 5.62 | pIC50 | 2400 | nM | IC50 | J Med Chem (2020) 63: 1750-1762 [PMID:32011136] |
| ChEMBL | Antiplasmodial activity against liver-stage GFP expressing Plasmodium berghei sporozoites infected in human HuH7 cells assessed as inhibition of parasite schizonts development after 48 hrs by FACS analysis | F | 5.7 | pIC50 | 2000 | nM | IC50 | J Med Chem (2009) 52: 7800-7807 [PMID:19799426] |
| ChEMBL | Antimalarial activity against liver stage Plasmodium berghei | F | 5.96 | pIC50 | 1100 | nM | IC50 | Eur J Med Chem (2021) 226: 113865-113865 [PMID:34655985] |
| Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
| ChEMBL | Antimalarial activity against Plasmodium falciparum 3D7A asexual forms assessed as inhibition of [G-3H]hypoxanthine uptake incubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 hrs by liquid scintillation spectrometry | F | 5 | pIC50 | >10000 | nM | IC50 | Eur J Med Chem (2020) 188: 111983-111983 [PMID:31911292] |
| ChEMBL | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 | F | 5 | pIC50 | >10000 | nM | IC50 | Bioorg Med Chem Lett (2007) 17: 6101-6106 [PMID:17900897] |
| ChEMBL | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis | F | 5.01 | pIC50 | 9860 | nM | IC50 | Eur J Med Chem (2018) 158: 68-81 [PMID:30199706] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes after 48 hrs by microscopy | F | 5.02 | pIC50 | 9650 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4666-4669 [PMID:18653332] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by [3H]hypoxanthine uptake | F | 5.11 | pIC50 | 7700 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4666-4669 [PMID:18653332] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcM29 after 48 hrs by [3H]hypoxanthine uptake | F | 5.14 | pIC50 | 7250 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4666-4669 [PMID:18653332] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1 after 48 hrs by [3H]hypoxanthine uptake | F | 5.16 | pIC50 | 6870 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4666-4669 [PMID:18653332] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1/Columbia after 48 hrs | F | 5.16 | pIC50 | 6870 | nM | IC50 | Eur J Med Chem (2010) 45: 2854-2859 [PMID:20362359] |
| ChEMBL | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum F32 after 48 hrs by [3H]hypoxanthine uptake | F | 5.17 | pIC50 | 6830 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4666-4669 [PMID:18653332] |
| ChEMBL | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum F32 after 48 hrs | F | 5.17 | pIC50 | 6830 | nM | IC50 | Eur J Med Chem (2010) 45: 2854-2859 [PMID:20362359] |
| ChEMBL | Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay | F | 5.22 | pIC50 | 6090 | nM | IC50 | J Med Chem (2013) 56: 7727-7740 [PMID:23927763] |
| ChEMBL | Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay | F | 5.23 | pIC50 | 5860 | nM | IC50 | J Med Chem (2013) 56: 7727-7740 [PMID:23927763] |
| ChEMBL | Antimalarial activity against asexual blood stage of chloroquine-susceptible Plasmodium falciparum 3D7 infected in human erythrocytes by [3H]-Hypoxanthine uptake assay | F | 5.24 | pIC50 | 5770 | nM | IC50 | Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum D10 by parasite lactate dehydrogenase assay | F | 5.24 | pIC50 | 5700 | nM | IC50 | Eur J Med Chem (2021) 215: 113227-113227 [PMID:33601312] |
| ChEMBL | Antimalarial activity against asexual blood stage of chloroquine-susceptible Plasmodium falciparum D6 infected in human erythrocytes by [3H]-Hypoxanthine uptake assay | F | 5.29 | pIC50 | 5160 | nM | IC50 | Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120] |
| ChEMBL | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 2 & 3) | F | 5.34 | pIC50 | 4580 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 1463-1472 [PMID:17242150] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum W2 by parasite lactate dehydrogenase assay | F | 5.36 | pIC50 | 4400 | nM | IC50 | Eur J Med Chem (2021) 215: 113227-113227 [PMID:33601312] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 | F | 5.48 | pIC50 | 3340 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 485-488 [PMID:18077165] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant blood stage Plasmodium falciparum W2 after 48 hrs by FACS analysis | F | 5.48 | pIC50 | 3300 | nM | IC50 | J Med Chem (2009) 52: 7800-7807 [PMID:19799426] |
| ChEMBL | Antimalarial activity against chloroquine-resistant erythrocyte stage of Plasmodium falciparum W2 after 48 hrs | F | 5.48 | pIC50 | 3300 | nM | IC50 | ACS Med Chem Lett (2014) 5: 108-112 [PMID:24900781] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 | F | 5.48 | pIC50 | 3300 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4150-4153 [PMID:18539459] |
| ChEMBL | Antimalarial activity against asexual blood stage of chloroquine-resistant Plasmodium falciparum W2 infected in human erythrocytes by [3H]-Hypoxanthine uptake assay | F | 5.63 | pIC50 | 2350 | nM | IC50 | Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum KT3 gametocytes | F | 5.68 | pIC50 | 2100 | nM | IC50 | J Med Chem (2012) 55: 10328-10344 [PMID:23075290] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum CQR (W2 clone) infected in human erythrocyte assessed as reduction in parasite growth incubated for 48 hrs by SYBR assay | F | 5.72 | pIC50 | 1900 | nM | IC50 | Bioorg Med Chem (2020) 28: 115832-115832 [PMID:33166927] |
| ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells after 48 hrs by SYBR test | F | 5.72 | pIC50 | 1890 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 1881-1884 [PMID:26988303] |
| ChEMBL | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 4 & 5) | F | 5.81 | pIC50 | 1540 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 1463-1472 [PMID:17242150] |
| ChEMBL | Antimalarial activity against multidrug-resistant Plasmodium falciparum W2 by SYBR green-based assay | F | 5.83 | pIC50 | 1470 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1100-1103 [PMID:25650255] |
| ChEMBL | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 asexual gametocytes | F | 5.88 | pIC50 | 1320 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 1463-1472 [PMID:17242150] |
| ChEMBL | Antiplasmodial activity against multidrug-resistant Plasmodium falciparum FCR-3 by [3H]-hypoxanthine incorporation assay | F | 5.93 | pIC50 | 1180 | nM | IC50 | Eur J Med Chem (2018) 152: 489-514 [PMID:29754074] |
| ChEMBL | Antiplasmodial activity against the multidrug-resistant Plasmodium falciparum FRC-3 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis | F | 5.96 | pIC50 | 1100 | nM | IC50 | Eur J Med Chem (2018) 158: 68-81 [PMID:30199706] |
| ChEMBL | Antiplasmodial activity against blood stage of chloroquine-sensitive Plasmodium falciparum NF54 by parasite lactate dehydrogenase assay | F | 6.05 | pIC50 | 892 | nM | IC50 | Eur J Med Chem (2015) 101: 266-273 [PMID:26142491] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum KT1 gametocytes | F | 6.1 | pIC50 | 800 | nM | IC50 | J Med Chem (2012) 55: 10328-10344 [PMID:23075290] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum K1 assessed as inhibition of [3H] hypoxanthine uptake by liquid scintillation counting | F | 6.19 | pIC50 | 643 | nM | IC50 | ACS Med Chem Lett (2013) 4: 128-131 [PMID:24900574] |
| ChEMBL | Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum 3D7 | F | 6.34 | pIC50 | 460 | nM | IC50 | Eur J Med Chem (2015) 90: 280-295 [PMID:25461328] |
| ChEMBL | Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 | F | 6.34 | pIC50 | 460 | nM | IC50 | Eur J Med Chem (2015) 90: 280-295 [PMID:25461328] |
| ChEMBL | Antimicrobial activity against Plasmodium falciparum Dd2 | F | 6.34 | pIC50 | 460 | nM | IC50 | Eur J Med Chem (2015) 90: 280-295 [PMID:25461328] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum FCR-3 sporozoites infected in human primary hepatocytes treated simultaneously with infection by DAPI staining based HCS analysis | F | 6.4 | pIC50 | 400 | nM | IC50 | Eur J Med Chem (2018) 152: 489-514 [PMID:29754074] |
| ChEMBL | Antiplasmodial activity against GFP-harboring Plasmodium falciparum sporozoites infected in human primary hepatocytes assessed as reduction in parasite growth treated every 24 hrs by DAPI staining-based fluorescence microscopic analysis | F | 6.4 | pIC50 | 400 | nM | IC50 | Eur J Med Chem (2018) 158: 68-81 [PMID:30199706] |
| ChEMBL | Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay | F | 6.49 | pIC50 | 326 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 3131-3134 [PMID:19364853] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine incorporation assay | F | 6.49 | pIC50 | 326 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 3131-3134 [PMID:19364853] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum W2 gametocytes assessed as suppression of parasitemia after 4 hrs by Giemsa staining | F | 8.05 | pIC50 | 8.9 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4393-4398 [PMID:19667291] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum FcB1/Columbia assessed as suppression of parasitemia after 4 hrs by Giemsa staining | F | 8.05 | pIC50 | 8.9 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4393-4398 [PMID:19667291] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum W2 assessed as suppression of parasitemia after 4 hrs by Giemsa staining | F | 8.15 | pIC50 | 7.14 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4393-4398 [PMID:19667291] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum F32 assessed as suppression of parasitemia after 4 hrs by Giemsa staining | F | 8.21 | pIC50 | 6.17 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4393-4398 [PMID:19667291] |
| Plasmodium yoelii (target type: ORGANISM) [ChEMBL: CHEMBL612889] | ||||||||
| ChEMBL | Antiplasmodial activity against GFP-harboring Plasmodium yoelii sporozoites infected in human HepG2 cells expressing CD81 assessed as reduction in parasite growth treated every 24 hrs by DAPI staining-based fluorescence microscopic analysis | F | 5.67 | pIC50 | 2130 | nM | IC50 | Eur J Med Chem (2018) 158: 68-81 [PMID:30199706] |
| ChEMBL | Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis | F | 5.94 | pIC50 | 1160 | nM | IC50 | Eur J Med Chem (2015) 95: 16-28 [PMID:25791675] |
| ChEMBL | Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin | F | 6 | pIC50 | <1000 | nM | IC50 | J Med Chem (2013) 56: 7761-7771 [PMID:23927658] |
| ChEMBL | Antimalarial activity against liver stages of Plasmodium yoelii 265 BY infected in Swiss mouse after 48 hrs by fluorescence microscopy | F | 7.12 | pIC50 | 75 | nM | IC50 | J Med Chem (2012) 55: 995-1012 [PMID:22122518] |
| Plasmodium yoelii yoelii (target type: ORGANISM) [ChEMBL: CHEMBL612328] | ||||||||
| ChEMBL | Antimalarial activity against Plasmodium yoelii 265 sporozoites in primary mice (Mus musculus) hepatocytes after 48 hrs | F | 6.19 | pIC50 | 640 | nM | IC50 | Bioorg Med Chem (2008) 16: 6186-6192 [PMID:18456502] |
| ChEMBL | Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs | F | 7.12 | pIC50 | 75.7 | nM | IC50 | Antimicrob Agents Chemother (2008) 52: 1215-1220 [PMID:18212104] |
| ChEMBL | Antimalarial activity against liver stages of Plasmodium yoelii yoelii | F | 7.12 | pIC50 | 75.7 | nM | IC50 | J Med Chem (2012) 55: 995-1012 [PMID:22122518] |
| Quinone reductase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3959] [UniProtKB: P16083] | ||||||||
| ChEMBL | Inhibition of human recombinant NQO2 | B | 5.12 | pIC50 | 7500 | nM | IC50 | Bioorg Med Chem Lett (2010) 20: 7331-7336 [PMID:21074425] |
| Serine hydroxymethyltransferase, mitochondrial in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4295747] [UniProtKB: P34897] | ||||||||
| ChEMBL | Inhibition of His-tagged human recombinant SHMT2 expressed in Escherichia coli BLR(DE3) assessed as reduction in NADPH level using L-serine, THF and NADP+ incubated for 5 mins by SHMT2-MTHFD coupled reaction based fluorescence assay | B | 6.36 | pIC50 | 436.52 | nM | IC50 | WO-2016085990-A1. Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity (2016) |
| SERT/Serotonin transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645] | ||||||||
| ChEMBL | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | B | 8.08 | pKi | 8.4 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | B | 7.8 | pIC50 | 16 | nM | IC50 | DrugMatrix in vitro pharmacology data |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
